1 / 1

LEAD-6

LEAD-6. Mean change in HbA 1c : -1.12% with liraglutide vs. -0.79% with exenatide (p < 0.0001) Proportion of patients with HbA 1c <7.0%: 54% vs. 43% (p = 0.0015), respectively Weight loss: -3.24 kg vs. -2.87 kg (p = NS), respectively.

corbin
Télécharger la présentation

LEAD-6

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LEAD-6 Mean change in HbA1c: -1.12% with liraglutide vs. -0.79% with exenatide (p < 0.0001) Proportion of patients with HbA1c <7.0%: 54% vs. 43% (p = 0.0015), respectively Weight loss: -3.24 kg vs. -2.87 kg (p = NS), respectively Trial design: Patients with type 2 diabetes on maximal doses of metformin, sulfonylurea, or both were randomized to liraglutide 1.8 mg daily (n = 233) vs. exenatide 10 µg twice daily (n = 231) for 26 weeks. Results p < 0.0001 % Conclusions -0.79 • In type 2 diabetes patients, use of liraglutide for 26 weeks was associated with improved glycemic control compared with exenatide • Liraglutide resulted in a greater reduction in mean HbA1c, and a greater proportion of patients who achieved target HbA1c levels -1.12 Mean change in HbA1c Liraglutide Exenatide Buse JB, et al. Lancet 2009;June 8:[Epub ahead of print]

More Related